Pancreatic Disease: Basic Science and Clinical Management summarises the state of the art in basic science and clinical management of pancreatic disease. This book provides a clear and up-to-date review of the advancing areas in clinical pancreatology and clinical research related to the pancreas. Written by leading experts in the field, this comprehensive review directs the interested reader towards important and current published source material.

Covering all aspects of pancreatic disease, contributions are included from pancreatic surgeons and medical pancreatologists on pancreatic cancer, acute pancreatitis and chronic pancreatitis. Special features include a systematic review of the evidence for the use of gemcitabine in pancreatic cancer prepared for the National Institute of Clinical Excellence (NICE), the UK body charged with evaluating new drug treatment. Gemcitabine has FDA approval. There are several contributions dealing with the management of pancreatic neuroendocrine tumours.

This book will be useful to gastroenterologists, internists and surgeons, and specialist clinicians with an interest in pancreatic disease. Trainees in medical and surgical pancreatology will find it a companion to supplement standard textbooks.

Pancreatic Disease: Basic Science and Clinical Management summarises the state of the art in basic science and clinical management of pancreatic disease. This book provides a clear and up-to-date review of the advancing areas in clinical pancreatology and clinical research related to the pancreas. Written by leading experts in the field, this comprehensive review directs the interested reader towards important and current published source material. Covering all aspects of pancreatic disease, contributions are included from pancreatic surgeons and medical pancreatologists on pancreatic cancer, acute pancreatitis and chronic pancreatitis. Special features include a systematic review of the evidence for the use of gemcitabine in pancreatic cancer prepared for the National Institute of Clinical Excellence (NICE), the UK body charged with evaluating new drug treatment. Gemcitabine has FDA approval. There are several contributions dealing with the management of pancreatic neuroendocrine tumours. This book will be useful to gastroenterologists, internists and surgeons, and specialist clinicians with an interest in pancreatic disease. Trainees in medical and surgical pancreatology will find it a companion to supplement standard textbooks.

Pancreatic Disease: Towards the Year 2000 provides a clear picture of the current research activity in pancreatic disease and its related basic science. Experts currently contributing to advances in understanding and treatment have provided concise and clear reviews of their subject. Each contribution summarises the relevant literature and describes recent advances whilst highlighting those areas where current research will impinge on clinical practice in the next few years. The reader will find in this book all the latest material related to pancreatic disease, cancer, acute and chronic pancreatitis and a number of other topics including transplantation and the relationship between endocrine and exocrine disease and cystic fibrosis. The book will supplement existing texts and will be of value to practising specialists who deal with pancreatic disease as well as specialist trainees in surgery and medical gastroenterology.